Skip to main content
SpringerLink
Log in

Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder

  • ORIGINAL PAPER
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

Outcome in schizophrenia is multidimensional and, thus, consists of clinical,humanitarian, rehabilitative and cost domains. Accordingly, recovery is conceptualized as the ability to function in the community, socially and vocationally, as well as being relatively free of disease–related psychopathology. The present cross–sectional study examined the relationship of premorbid functioning, psychopathology, insight, attitudes toward medication and side–effects, as well as sociodemographic factors with treatment outcomes in terms of quality of life (QOL) and psychosocial functioning among 60 regular attendees of a specialized schizophrenia outpatient clinic. Both insight into the illness as well as attitudes toward treatment indicated satisfactory compliance. Premorbid school and social functioning were positively correlated with actual employment status, and premorbid social functioning was further positively correlated with QOL and global functioning. Attitudes toward treatment were positively associated with global QOL, and with the patients' living situation. Both positive and negative symptoms as well as asthenia were negatively associated with QOL, while cognitive symptoms negatively influenced occupational functioning. Older patients lived independently and/or in a partnership more often, but had a lesser likelihood of competitive employment. Our observations suggest that subjective and functional outcomes in highly compliant patients are mainly predicted by psychopathological symptoms and unchangeable sociodemographic variables.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Addington J, Addington D (1993) Premorbid functioning, cognitive functioning, symptoms, and outcome in schizophrenia. J Psychiatry Neurosci 18:18–23

    PubMed  CAS  Google Scholar 

  2. Allison DB, Mackell JA, McDonnell DD (2003) The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 54:565–567

    Article  PubMed  Google Scholar 

  3. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. APA, Washington D. C.

  4. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441–449

    Article  PubMed  Google Scholar 

  5. Andreasen NC, Flaum M, Arndt S (1992) The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 49:615–623

    PubMed  CAS  Google Scholar 

  6. Awad AG, Hogan TP (1994) Subjective response to neuroleptics and quality of life: implications for treatment outcome. Acta Psychiatr Scand 89(Suppl 380):27–31

    Google Scholar 

  7. Awad AG, Hogan TP, Voruganti LN, Heslegrave RJ (1995) Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 10(Suppl 3):123–132

    PubMed  Google Scholar 

  8. Bailer J, Brauer W, Rey ER (1996) Premorbid adjustment as predictor of outcome in schizophrenia: results of a prospective study. Acta Psychiatr Scand 93:368–377

    PubMed  CAS  Google Scholar 

  9. Beiser M, Bean G, Erickson D, Zhan J, Iacono WG, Rector NA (1994) Biological and psychosocial predictors of job performance following a first episode of psychosis. Am J Psychiatry 151:857–863

    PubMed  CAS  Google Scholar 

  10. Breier A, Schreiber JL, Dyer J, Pickar D (1991) National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry 48:239–246

    PubMed  CAS  Google Scholar 

  11. Brekke JS, Levin S, Wolkon G, Sobel G, Slade B (1993) Psychosocial functioning and subjective experience in schizophrenia. Schizophr Bull 19:599–608

    PubMed  CAS  Google Scholar 

  12. Browne S, Garavan J, Gervin M, Roe M, Larkin C, O'Callaghan C (1998) Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nerv Ment Dis 186:74–78

    Article  PubMed  CAS  Google Scholar 

  13. Browne S, Clarke M, Gervin M, Waddington JL, Larkin C, O'Callaghan E (2000) Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatry 176:173–176

    Article  PubMed  CAS  Google Scholar 

  14. Cabeza IG, Amador MS, Lopez CA, Conzalez de Chavez M (2000) Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 41:349–355

    Article  PubMed  CAS  Google Scholar 

  15. Cannon–Spoor HE, Potkin SG, Wyatt RJ (1982) Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 8:470–484

    PubMed  CAS  Google Scholar 

  16. DeJong A, Giel R, Slooff CJ, Wiersma D (1986) Relationship between symptomatology and social disability. Empirical evidence from a follow–up study of schizophrenic patients. Soc Psychiatry 21:200–205

    Article  PubMed  CAS  Google Scholar 

  17. Dickerson F, Boronow JJ, Ringel N, Parente F (1999) Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2–year follow–up. Schizophr Res 37:13–20

    Article  PubMed  CAS  Google Scholar 

  18. Doyle M, Flanagan S, Browne S, Clarke M, Lydon D, Larkin C, O'Callaghan E (1999) Subjective and external assessments of quality of life in schizophrenia: relationship to insight. Acta Psychiatr Scand 99:466–472

    PubMed  CAS  Google Scholar 

  19. Fleischhacker WW (2002) Pharmacological treatment of schizophrenia: a review. In: Maj M, Sartorius N (eds) Schizophrenia. WPA Series Evidence and Experience in Psychiatry. John Wiley and Sons LTD, Chichester NY Weinheim Brisbane Singapore Toronto, pp 75–113

  20. Fleischhacker WW, Rabinowitz J, Kemmler G, Lasser RA, Mehnert A (2005) Perceiving functioning, well–being and association with psychiatric symptomatology in clinically stable schizophrenia patients treated with long–acting risperidone for 1 year. Br J Psychiatry (in press)

  21. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC (2004) Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 65:1372–1376

    Article  PubMed  Google Scholar 

  22. Gaite L, Vázquez–Barquero JL, Borra C, Ballesteros J, Schene A, Welcher B, Thornicroft G, Becker T, Ruggeri M, Herran A (2002) Quality of life in patients with schizophrenia in five European countries: the EPSILON study. Acta Psychiatr Scand 105:283–292

    Article  PubMed  CAS  Google Scholar 

  23. Gervin M, Browne S, Garavan J, Roe M, Larkin C, O'Callaghan E (1999) Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry 14:405–409

    Article  PubMed  CAS  Google Scholar 

  24. Goldberg RW, Green–Paden LD, Lehman AF, Gold JM (2001) Correlates of insight in serious mental illness. J Nerv Ment Dis 189:137–145

    Article  PubMed  CAS  Google Scholar 

  25. Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker WW (2002) Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 63:49–53

    PubMed  Google Scholar 

  26. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW (2004) Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 65:932–939

    PubMed  Google Scholar 

  27. Hofer A, Baumgartner S, Edlinger M, Hummer M, Kemmler G, Rettenbacher MA, Schweigkofler H, Schwitzer J, Fleischhacker WW (2005) Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry (in press)

    Google Scholar 

  28. Hofer A, Baumgartner S, Bodner T, Edlinger M, Hummer M, Kemmler G, Rettenbacher MA, Fleischhacker WW (2005) Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry (in press)

    Google Scholar 

  29. Hogan TP, Awad AG, Eastwood R (1983) A self–report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13:177–183

    Article  PubMed  CAS  Google Scholar 

  30. Kay SR, Fiszbein A, Opler LA (1997) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276

    Google Scholar 

  31. Kemmler G, Holzner B, Neudorfer C, Meise U, Hinterhuber H (1997) General life satisfaction and domain–specific quality of life in chronic schizophrenic patients. Qual Life Res 6:265–273

    Article  PubMed  CAS  Google Scholar 

  32. Lambert M, Naber D (2004) Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 18(Suppl 2):5–17

    Article  PubMed  Google Scholar 

  33. Leary J, Johnstone EC, Owens DGC (1991) Social outcome. Br J Psychiatry 159(Suppl 13):13–21

    Google Scholar 

  34. Lindenmayer JP, Bernstein–Hyman R, Grochowski S (1994) Fivefactor model of schizophrenia. J Nerv Ment Dis 182:631–638

    Article  PubMed  CAS  Google Scholar 

  35. Lindenmayer JP, Grochowski S, Hyman RB (1995) Five factor model of schizophrenia: replication across samples. Schizophr Res 14:229–234

    Article  PubMed  CAS  Google Scholar 

  36. Lindstrom LH (1996) Clinical and biological markers for outcome in schizophrenia: a review of a longitudinal follow–up study in Uppsala schizophrenia research project. Neuropsychopharmacology 14(Suppl 3):23S–26S

    Article  PubMed  CAS  Google Scholar 

  37. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU Side Effect Rating Scale – a new comprehensive rating scale for psychotropic drugs and a cross–sectional study of side effects in neuroleptic–treated patients. Acta Psychiatr Scand 334(Suppl):1–100

    CAS  Google Scholar 

  38. Lysaker P, Bell M, Milstein R, Bryson G, Beam–Goulet J (1994) Insight and psychosocial treatment compliance in schizophrenia. Psychiatry 57:307–315

    PubMed  CAS  Google Scholar 

  39. McEvoy JP, Apperson LJ, Apfelbaum PS, Ortlip P, Brecosky J, Hammill K, Geller JL, Roth L (1989) Insight in schizophrenia. Its relationship to acute psychopathology. J Nerv Ment Dis 177:43–47

    PubMed  CAS  Google Scholar 

  40. McGlashan TH (1988) A selective review of recent North American long–term follow–up studies of schizophrenia. Schizophr Bull 14:515–542

    PubMed  CAS  Google Scholar 

  41. McGurk S, Moriarty PJ, Harvey PD, Parrella M, White L, Davis KL (2000) The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia. Schizophr Res 42:47–55

    Article  PubMed  CAS  Google Scholar 

  42. McGurk SR, Mueser KT (2003) Cognitive functioning and employment in severe mental illness. J Nerv Ment Dis 191:789–798

    PubMed  Google Scholar 

  43. Mueser KT (2000) Cognitive functioning, social adjustment, and long–term outcome in schizophrenia. In: Sharma T, Harvey P (eds) Cognition in Schizophrenia. Oxford University Press, New York NY, pp 157–177

  44. Mueser KT (2002) Cognitive impairment, symptoms, social functioning, and vocational rehabilitation in schizophrenia. In: Kashima H, Falloon IRH, Mizuno M, Asai M (eds) Comprehensive treatment of schizophrenia: linking neurobehavioral findings to psychosocial approaches. Sprinter–Verlag, Tokyo, pp 344–351

  45. Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R (2005) Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv 56:273–282

    Article  PubMed  Google Scholar 

  46. Prudo R, Monroe–Blum H (1987) Five year outcome and prognosis in schizophrenia; a report from the London field centre of the international pilot study of schizophrenia. Br J Psychiatry 150:345–354

    Article  PubMed  CAS  Google Scholar 

  47. Racenstein JM, Harrow M, Reed R, Martin E, Herbener E, Penn DL (2002) The relationship between positive symptoms and instrumental work functioning in schizophrenia: a 10 year followup study. Schizophr Res 56:95–103

    Article  PubMed  Google Scholar 

  48. Ritsner M, Modai I, Endicott J, Ravkin O, Nechamkin Y, Barak P, Goldin V, Ponizovsky A (2000) Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry 61:880–889

    PubMed  CAS  Google Scholar 

  49. Ritsner M, Kurs R, Gibel A, Hirschmann S, Shinkarenko E, Ratner Y (2003) Predictors of quality of life in major psychoses: a naturalistic follow–up study. J Clin Psychiatry 64:308–315

    Article  PubMed  Google Scholar 

  50. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA (2002) Predictors of medication discontinuation by patients with first–episode schizophrenia and schizoaffective disorder. Schizophr Res 57:209–219

    Article  PubMed  Google Scholar 

  51. Sim K, Mahendran R, Siris SG, Heckers S, Chong SA (2004) Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res 129:141–147

    Article  PubMed  Google Scholar 

  52. Strauss JS, Carpenter WT (1972) The prediction of outcome in schizophrenia I: characteristics of outcome. Arch Gen Psychiatry 17:739–746

    Google Scholar 

  53. The WHOQOL Group (1998) Development of the World Health Organization WHOQOL–BREF quality of life assessment. Psychol Med 28:551–558

    Article  Google Scholar 

  54. Thornicroft G, Tansella M, Becker T, Knapp M, Leese M, Schene A (2004) The personal impact of schizophrenia in Europe. Schizophr Res 69:125–132

    Article  PubMed  Google Scholar 

  55. Ucok A, Polat A, Cakir S, Genc A (2005) One year outcome in first episode schizophrenia. Predictors of relapse. Eur Arch Psychiatry Clin Neurosci

  56. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, Awad A (2002) Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 57:201–208

    Article  PubMed  CAS  Google Scholar 

  57. Weiden PJ, Shaw E, Mann JJ (1986) Causes of neuroleptic noncompliance. Psychiatr Ann 16:571–575

    Google Scholar 

  58. Weiden P, Aquila R, Standard J (1996) Atypical antipsychotic drugs and long–term outcome in schizophrenia. J Clin Psychiatry 57(Suppl 11):53–60

    PubMed  CAS  Google Scholar 

  59. Williams CC, Collins A (2002) Factors associated with insight among outpatients with serious mental illness. Psychiatr Serv 53:96–98

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical University Innsbruck, Department of Biological Psychiatry, Anichstrasse 35, 6020, Innsbruck, Austria

    A. Hofer M.D., M. A. Rettenbacher, Ch. G. Widschwendter, G. Kemmler, M. Hummer & W. W. Fleischhacker

Authors
  1. A. Hofer M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. Rettenbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ch. G. Widschwendter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Kemmler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Hummer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. W. Fleischhacker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Hofer M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hofer, A., Rettenbacher, M.A., Widschwendter, C.G. et al. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci 256, 246–255 (2006). https://doi.org/10.1007/s00406-005-0633-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-005-0633-3

Key words

Search

Navigation